Sponsors (16)
The bill funds a federal Center to accelerate U.S. biopharmaceutical manufacturing, workforce development, and supply resilience, trading significant taxpayer investment and risks of concentrated benefits, private IP capture, and potential defense-oriented priorities for faster domestic production and industry growth.
Scientists, researchers, manufacturers, and biotech startups gain a federally supported Center that accelerates scaling lab innovations into commercial biopharmaceutical production and R&D standardization.
Hospitals, health systems, taxpayers, and patients benefit from strengthened U.S. biomanufacturing capacity and supply resilience, reducing reliance on foreign supply chains for critical medicines and materials.
Students and workers receive expanded training and workforce development tied to industry partnerships and upgraded facilities, strengthening the biotech talent pipeline.
Taxpayers would fund establishment and operation of the Center, including a $120 million FY2026 authorization, with no guarantee of successful outcomes or full return on investment.
Funding and benefits may concentrate at a single selected institution and established research hubs, creating geographic and institutional barriers for smaller innovators and rural communities and potentially crowding out alternative regional or private investments.
Private partners in jointly funded R&D could obtain intellectual property rights that limit public access or raise costs for new therapies, affecting patients and healthcare providers.
Based on analysis of 3 sections of legislative text.
Authorizes NIST to competitively establish and fund a single National Biopharmaceutical Manufacturing Center of Excellence and authorizes $120M for FY2026 to support research, scaling, standards, and training.
Introduced November 18, 2025 by Christina Houlahan · Last progress November 18, 2025
Creates a federally supported National Biopharmaceutical Manufacturing Center of Excellence run through the National Institute of Standards and Technology (NIST). NIST must competitively award a single grant or other transaction agreement to an eligible non‑Federal entity (such as a public‑private partnership, university, or consortium) to build and operate the center, support research to scale biopharmaceutical manufacturing, develop standards and interagency data sharing, fund workforce training and facility construction as needed, and report to Congress on progress. The bill authorizes $120,000,000 for FY2026 and sets application, selection, IP-guidance, and reporting requirements.